HLA-A2 Positive Cells Present

Clinical trial pipeline · Data from ClinicalTrials.gov

See which HLA-A2 Positive Cells Present trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT06472245

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immu…

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistanc…

United States363 participantsStarted 2024-12-03

Treatment: OSE2101, Docetaxel

All recent trials (24 shown)

TerminatedPhase 2

NCT04093323

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HL…

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating pa…

United States1 participantsStarted 2024-11-13

Treatment: Alpha-type-1 Polarized Dendritic Cells, Celecoxib

Active — Not RecruitingPhase 1

NCT02869217

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, whic…

Canada22 participantsStarted 2016-09

Treatment: Cyclophosphamide, TBI-1301

HLA-A2 Positive Cells Present

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immu…

All recent trials (24 shown)

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HL…

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immu…

All recent trials (24 shown)

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HL…

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

AFPᶜ³³²T in Advanced HCC

Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherap…

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzum…

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymph…

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineer…